Early May marked the start of an important new phase in the fight against type 1 diabetes. For the first time, a patient who was still able to produce some insulin of their own has been treated with a so‑called inverse vaccine: a therapy designed not to activate the immune system, but to calm it.

Cure One researcher Dr. René van Tienhoven has been elected a ‘Rising Star’ by the international Immunology of Diabetes Society during its congress in Brisbane, Australia, on 21 April 2026.

INNODIA is a leading European collaborative initiative focused on innovation in type 1 diabetes research and is currently actively working on the establishment of a clinical research site.

On November 14, Cure One was officially opened during a talk show at LUMC. Hosts Klaas van Kruistum and Roxanne Kwant give us a behind-the-scenes look at the brand-new research center. You can watch the talk show again below.

Françoise Carlotti and her team receive EUR600.000,- from Breakthrough T1D to optimize production of 'stem cell islets'

On World Diabetes Day, the new Cure One research center was officially opened by Peter Heijkoop, the mayor of Leiden.

Professor Bart Roep and his team are working on a groundbreaking approach to not only treat type 1 diabetes (T1D) but potentially even cure it.

Researchers at LUMC have developed a method for enhancing the purity of insulin-producing islets generated from stem cells in the laboratory.

In collaboration with the Diabetes Research Foundation Netherlands (DON), a new leading research center for type 1 diabetes (T1D) is being launched at Leiden University Medical Center (LUMC) under the name Cure One.

LUMC scientists have discovered how hereditary predisposition determines the risk of type 1 diabetes.

The launch of Cure One has not gone unnoticed. Major national media outlets covered the event extensively, including Trouw, NOS, NPO Radio 1, Editie NL, and Hart van Nederland.